New Drug Approvals

Home » Uncategorized » Ladostigil

Ladostigil

DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO .....FOR BLOG HOME CLICK HERE

PAYPAL DONATIONS

ORGANIC SPECTROSCOPY

Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 

Categories

Blog Stats

  • 1,308,555 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,781 other followers

add to any

Share

Ladostigil.png

Ladostigil.png

Ladostigil, TV-3,326

(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate

(3R)-3-(Prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate; R-CPAI

Carbamic acid, ethylmethyl-, (3R)-2,3-dihydro-3-(2-propynylamino)-1H-inden-5-yl ester

Condition(s): Mild Cognitive Impairment
U.S. FDA Status: Mild Cognitive Impairment (Phase 2)
Company: Avraham Pharmaceuticals Ltd

Target Type: Cholinergic System

CAS No: 209349-27-4
Synonyms: Ladostigil, TV-3326, UNII-SW3H1USR4Q
Molecular Weight: 272.346 g/mol
Chemical Formula: C16-H20-N2-O2
IUPAC Name: (3R)-3-(Prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate N-Propargyl-(3R)-aminoindan-5-yl) ethyl methyl carbamate

Ladostigil tartrate Structure

CAS 209394-46-7, Ladostigil tartrate

N-Ethyl-N-methylcarbamic acid 3(R)-(2-propynylamino)-2,3-dihydro-1H-inden-5-yl ester L-tartrate

In 2010, ladostigil tartrate was licensed by Technion Research & Development Foundation and Yissum to Avraham for the treatment of Alzheimer’s disease and other neurogenerative diseases.

Ladostigil (TV-3,326) is a novel neuroprotective agent being investigated for the treatment of neurodegenerative disorders likeAlzheimer’s disease, Lewy body disease, and Parkinson’s disease.[1] It acts as a reversible acetylcholinesterase andbutyrylcholinesterase inhibitor, and an irreversible monoamine oxidase B inhibitor, and combines the mechanisms of action of older drugs like rivastigmine and rasagiline into a single molecule.[2][3] In addition to its neuroprotective properties, ladostigil enhances the expression of neurotrophic factors like GDNF and BDNF, and may be capable of reversing some of the damage seen in neurodegenerative diseases via the induction of neurogenesis.[4] Ladostigil also has antidepressant effects, and may be useful for treating comorbid depression and anxiety often seen in such diseases as well.[5][6]

Ladostigil [(N-propargyl-(3R) aminoindan-5yl)-ethyl methyl carbamate] is a dual acetylcholine-butyrylcholineesterase and brain selective monoamine oxidase (MAO)-A and -B inhibitor in vivo (with little or no MAO inhibitory effect in the liver and small intestine), intended for the treatment of dementia co-morbid with extrapyramidal disorders and depression (presently in a Phase IIb clinical study). This suggests that the drug should not cause a significant potentiation of the cardiovascular response to tyramine, thereby making it a potentially safer antidepressant than other irreversible MAO-A inhibitors. Ladostigil was shown to antagonize scopolamine-induced impairment in spatial memory, indicating that it can cause significant increases in rat brain cholinergic activity. Furthermore, ladostigil prevented gliosis and oxidative-nitrative stress and reduced the deficits in episodic and spatial memory induced by intracerebroventricular injection of streptozotocin in rats. Ladostigil was demonstrated to possess potent anti-apoptotic and neuroprotective activities in vitro and in various neurodegenerative rat models, (e.g. hippocampal damage induced by global ischemia in gerbils and cerebral oedema induced in mice by closed head injury). These neuroprotective activities involve regulation of amyloid precursor protein processing; activation of protein kinase C and mitogen-activated protein kinase signaling pathways; inhibition of neuronal death markers; prevention of the fall in mitochondrial membrane potential and upregulation of neurotrophic factors and antioxidative activity. Recent findings demonstrated that the major metabolite of ladostigil, hydroxy-1-(R)-aminoindan has also a neuroprotective activity and thus, may contribute to the overt activity of its parent compound. This review will discuss the scientific evidence for the therapeutic potential use of ladostigil in Alzheimer’s and Lewy Body diseases and the molecular signaling pathways that are considered to be involved in the biological activities of the drug

PAPER

Tetrahedron: Asymmetry (2012), 23(5), 333-338

http://www.sciencedirect.com/science/article/pii/S0957416612001334

Image for unlabelled figure

Graphical absImg(R)-3-(Prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl ethyl(methyl)carbamate

C16H20N2O2

ee: 89%

View the MathML source (c 1.46, CHCl3)

Source of chirality: the precursor

Absolute configuration: (R)

Contact Us

Yona Geffen CEO
Avraham Pharmaceuticals Ltd.
42 Hayarkon st.
Northern Industrial Zone
Yavneh, 81227
Israel

WO1998027055A1 * 18 Dec 1997 25 Jun 1998 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
WO2005051371A1 28 Sep 2004 9 Jun 2005 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
WO2006130726A2 31 May 2006 7 Dec 2006 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
WO2007087029A2 * 11 Dec 2006 2 Aug 2007 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of low-dose ladostigil for neuroprotection
WO2009022345A1 14 Aug 2008 19 Feb 2009 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
WO2009022346A2 14 Aug 2008 19 Feb 2009 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for treating gastrointestinal inflammation
WO2012059920A1 2 Nov 2011 10 May 2012 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil dosage regime
US6251938 18 Jun 1999 26 Jun 2001 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US6303650 18 Jun 1999 16 Oct 2001 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
US6538025 31 Aug 2001 25 Mar 2003 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US7335685 22 Feb 2006 26 Feb 2008 Teva Pharmaceutical Industries, Ltd. Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US7375249 21 Feb 2006 20 May 2008 Teva Pharmaceutical Industries Ltd. Process for the synthesis of enantiomeric indanylamine derivatives
US7476757 15 Apr 2008 13 Jan 2009 Teva Pharmaceutical Industries Ltd. Process for the synthesis of enantiomeric indanylamine derivatives
US7491847 15 Nov 2006 17 Feb 2009 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US20050222123 27 Jan 2005 6 Oct 2005 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
US20060189685 24 Feb 2006 24 Aug 2006 Daniella Licht Formulations of ladostigil tartrate
US20060189819 22 Feb 2006 24 Aug 2006 Teva Pharmaceutical Industries, Ltd. Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
US20060199974 21 Feb 2006 7 Sep 2006 Teva Pharmaceutical Industries Ltd. Process for the synthesis of enantiomeric indanylamine derivatives
US20070088082 28 Sep 2006 19 Apr 2007 Judith Aronhime Polymorphic forms of ladostigil tartrate
US20070093549 28 Sep 2006 26 Apr 2007 Judith Aronhime Methods for preparation of ladostigil tartrate crystalline form A1
US20070112217 15 Nov 2006 17 May 2007 Anton Frenkel Methods for isolating propargylated aminoindans
US20070135518 8 Dec 2006 14 Jun 2007 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
US20070203232 23 Feb 2007 30 Aug 2007 Victor Piryatinsky Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691 28 Mar 2007 4 Oct 2007 Tamar Goren Use of ladostigil for the treatment of schizophrenia
US20070293583 11 Dec 2006 20 Dec 2007 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
US5532415 * Mar 28, 1995 Jul 2, 1996 Teva Pharmaceutical Industries Ltd. R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
US5703059 * Jan 19, 1994 Dec 30, 1997 British Biotech Pharmaceuticals Ltd. Disaccharide ligands for selectins
US5936000 * Jan 16, 1996 Aug 10, 1999 Pharmacia & Upjohn Company 2-aminoindans as selective dopamine D3 ligands
US6271261 * Jun 24, 1997 Aug 7, 2001 Smithkline Beecham Corporation IL-8 receptor antagonists
US6271263 * Mar 2, 1999 Aug 7, 2001 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US6303650 * Jun 18, 1999 Oct 16, 2001 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
US6462222 * Aug 31, 2001 Oct 8, 2002 Yissum Research Development Company Of The Hebrew University Of Jerusalem Aminoindan derivatives
US6538025 * Aug 31, 2001 Mar 25, 2003 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
US6737547 * Sep 15, 1999 May 18, 2004 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
US20040010038 * Feb 27, 2003 Jan 15, 2004 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
Citing Patent Filing date Publication date Applicant Title
US7649115 Jun 1, 2006 Jan 19, 2010 Jenrin Discovery, Inc. MAO-B inhibitors useful for treating obesity
US8541475 Dec 31, 2009 Sep 24, 2013 Jenrin Discovery, Inc. MAO-B inhibitors useful for treating obesity
US8569545 Jun 2, 2009 Oct 29, 2013 Generics (Uk) Limited Process for the preparation of enantiomerically pure amines
US8809589 Jul 18, 2013 Aug 19, 2014 Generics [Uk] Limited Process for the preparation of enantiomerically pure amines
US20070088004 * Jun 1, 2006 Apr 19, 2007 Mcelroy John F MAO-B inhibitors useful for treating obesity
US20100168068 * Dec 31, 2009 Jul 1, 2010 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US20110184071 * Jun 2, 2009 Jul 28, 2011 Vinayak Gore process for the preparation of amines
US20110218360 * Sep 8, 2011 Dr. Reddy’s Laboratories Ltd. Preparation of rasagiline and salts thereof
CN103443111A * Apr 2, 2012 Dec 11, 2013 高砂香料工业株式会社 Novel ruthenium complex and process for producing optically active alcohol compound using same as catalyst
CN103443111B * Apr 2, 2012 Mar 2, 2016 高砂香料工业株式会社 钌配合物以及以该配合物作为催化剂的光学活性醇化合物的制备方法
WO2013118126A1 Feb 11, 2013 Aug 15, 2013 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil therapy for immunomodulation
Ladostigil
Ladostigil.png
Systematic (IUPAC) name
[(3R)-3-(prop-2-ynylamino)indan-5-yl]-N-propylcarbamate
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 209349-27-4
ATC code none
PubChem CID 208907
ChemSpider 181005
UNII SW3H1USR4Q Yes
Synonyms [N-propargyl-(3R)-aminoindan-5yl]-N-propylcarbamate
Chemical data
Formula C16H20N2O2
Molar mass 272.34 g/mol

///////////Ladostigil, TV-3,326

c1c(cc2c(c1)CC[C@H]2NCC#C)OC(=O)N(CC)C


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Paypal Donate

DR ANTHONY CRASTO

Follow New Drug Approvals on WordPress.com

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 1,781 other followers

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO Ph.D

DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 29 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure till date Aug 2016, Around 30 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 25 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email amcrasto@gmail.com, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 13 lakh plus views on New Drug Approvals Blog in 212 countries......https://newdrugapprovals.wordpress.com/ , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →

TWITTER

bloglovin

Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: